Canakinumab - Biologic Drug Details

Summary for canakinumab

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for canakinumab

Recent Clinical Trials for canakinumab

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Shenyang Northern Hospital	PHASE4
Massachusetts General Hospital	PHASE2
Broad Institute of MIT and Harvard	PHASE2

See all canakinumab clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for canakinumab Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for canakinumab Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Novartis Pharmaceuticals Corporation	ILARIS	canakinumab	For Injection	125319	7,446,175	2021-08-20	DrugPatentWatch analysis and company disclosures
Novartis Pharmaceuticals Corporation	ILARIS	canakinumab	Injection	125319	7,446,175	2021-08-20	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for canakinumab Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Novartis Pharmaceuticals Corporation	ILARIS	canakinumab	For Injection	125319	10,000,565	2033-11-14	Patent claims search
Novartis Pharmaceuticals Corporation	ILARIS	canakinumab	For Injection	125319	10,016,338	2036-12-20	Patent claims search
Novartis Pharmaceuticals Corporation	ILARIS	canakinumab	For Injection	125319	10,040,859	2035-04-21	Patent claims search
Novartis Pharmaceuticals Corporation	ILARIS	canakinumab	For Injection	125319	10,041,044	2037-07-28	Patent claims search
Novartis Pharmaceuticals Corporation	ILARIS	canakinumab	For Injection	125319	10,111,968	2036-08-10	Patent claims search
Novartis Pharmaceuticals Corporation	ILARIS	canakinumab	For Injection	125319	10,213,444	2035-12-04	Patent claims search
Novartis Pharmaceuticals Corporation	ILARIS	canakinumab	For Injection	125319	10,329,314	2038-02-28	Patent claims search

Canakinumab (Ilaris): Market Dynamics and Financial Trajectory

Last updated: April 25, 2026

What is canakinumab’s market role and commercial footprint?

Canakinumab (Ilaris) is a monoclonal antibody targeting interleukin-1β (IL‑1β). Commercially, it has been positioned around periodic dosing for IL‑1 mediated autoinflammatory disorders, with uptake driven by label fit, payer coverage, and clinician familiarity.

Key branded product

• Brand: Ilaris
• Active: canakinumab (IL‑1β inhibitor)
• Dosing pattern (typical): weight-based subcutaneous dosing for pediatric periodic fever syndromes and certain adult indications; dosing intervals vary by indication and label.

Which indications drive demand and how do label boundaries shape uptake?

Market dynamics for canakinumab are dominated by a small set of high-coverage, clinician-recognized diseases. Demand growth has tended to track (1) pediatric diagnosis rates and (2) payer acceptance of IL‑1 targeting after inadequate response to conventional therapies.

Principal labeled commercial anchors (selected)

• Cryopyrin-associated periodic syndromes (CAPS) including familial cold autoinflammatory syndrome (FCAS), Muckle-Wells syndrome (MWS), and neonatal-onset multisystem inflammatory disease (NOMID).
• Familial Mediterranean fever (FMF) patients with inadequate response to colchicine (where indicated).
• Systemic juvenile idiopathic arthritis (sJIA) and other juvenile inflammatory syndromes where IL‑1β inhibition is adopted after step therapies.
• Adult autoinflammatory indications in specific geographies and label versions.

How this affects market traction

• Diagnosis-driven penetration: Many target disorders are rare, so growth correlates with specialist case-finding and treatment initiation rather than broad population expansion.
• Payer gating: Because the indication set is narrow, formularies and prior authorization requirements are decisive. Payers often require documented disease subtype and prior therapy failure.
• Dosing consistency: Periodic dosing reduces adherence friction, which supports sustained revenue once patients start treatment.

What market forces shape pricing power and payer behavior?

Canakinumab’s revenue trajectory reflects a tug-of-war between high list prices and payer pressure, including:

• Biosimilar and competitive substitution risk (limited for canakinumab at various points because the market is drug-specific and biologics are harder to substitute without interchangeability approvals).
• Real-world cost-effectiveness scrutiny: IL‑1 inhibitors are priced as premium specialty biologics; payers respond by shifting uptake to the subset of patients most likely to achieve response.
• Tight budget control in Europe and managed care: In many markets, negotiation and rebates determine net pricing more than list price.

Commercial implication

• Revenue is typically resilient in the absence of direct biosimilar competition at scale, but growth rates can flatten when payers tighten criteria or when competitor products win preferred positioning in overlapping pathways.

How has the commercial trajectory changed over time?

Canakinumab’s financial path is best understood in stages: early expansion on label breadth and pediatric adoption, followed by a mature-phase plateau with periodic step-down from pricing pressure, channel management, and competitive dynamics.

Pattern seen in premium specialty biologics for rare disease

• Initial growth: driven by expanding label indications and increasing specialist awareness.
• Maturity: driven by continued patient retention and incremental net adds rather than rapid population expansion.
• Pressure periods: when net price declines via contracting, and when payer utilization controls increase.

What do financial disclosures show about canakinumab’s revenue direction?

Canakinumab revenue reporting historically appeared in company product sales disclosures as a major contributor within the IL‑1 franchise. In the mature period, the revenue profile has shifted from growth to stabilization, with later declines associated with pricing pressure and competitive forces in certain geographies and indications.

High-level financial reality

• Canakinumab is a mid-to-large revenue driver for the IL‑1 portfolio.
• Net revenue is sensitive to:
  • discounts/rebates,
  • tender outcomes (in government payer contexts),
  • loss of restricted formulary positions,
  • changes in patient mix by indication.

How does portfolio context influence canakinumab’s outlook?

Canakinumab competes in IL‑1 and IL‑1 pathway biologics and interacts with broader immunology product positioning (anti-inflammatory and systemic inflammatory disease portfolios). In practice, revenue can be affected by:

• pipeline and lifecycle management within the sponsor’s inflammation franchise,
• sequencing strategies against IL‑1 alternatives,
• sponsor promotional and patient support programs that sustain persistence.

What competitive dynamics matter most: IL‑1 pathway alternatives?

The IL‑1β treatment landscape includes IL‑1 receptor blockers and other IL‑1 pathway agents depending on region and indication. Canakinumab’s competitive advantage historically came from:

• specific efficacy evidence in CAPS and other IL‑1 driven phenotypes,
• a dosing schedule that supports sustained management,
• deep clinician familiarity in rare disease settings.

Competitive pressure typically shows up through:

• formulary preference in overlapping indications,
• switching behavior when alternative agents offer similar outcomes with different convenience or cost profiles,
• payer-driven step therapy and response-based reauthorization.

What are the biggest risk and revenue-resilience levers?

Revenue resilience levers

• Strong fit to rare, severe IL‑1 mediated diseases where IL‑1β inhibition is standard.
• Retention: chronic or recurring nature of indications supports ongoing treatment.
• Clinician familiarity: established therapeutic role reduces switching unless cost or competitive efficacy forces change.

Revenue downside levers

• Net price erosion: discounting and contracting pressure reduce realized revenue.
• Utilization restrictions: tighter prior authorization and reauthorization criteria.
• Geographic variability: public tenders and managed care protocols can rapidly reshape uptake.

How do manufacturing scale and supply constraints influence financial trajectory?

In premium biologics, supply stability is a financial lever. When supply is constrained, treatment initiation delays can reduce near-term revenue. When supply stabilizes, revenue returns with improved conversion.

For canakinumab, market impact has generally been limited by the chronic nature of treatment, where disruptions can still create delays in patient onboarding and refill cycles, affecting quarterly sales.

What does the market imply for near-to-mid term financial path?

The most likely trajectory in the absence of disruptive biosimilar entry or major label expansion is:

• Stable-to-slow growth driven by patient retention and incremental penetration.
• Net revenue pressure via contracting, especially where payers benchmark IL‑1 agents against each other.
• Indication mix shifts as certain subpopulations move through different treatment algorithms.

Investment-grade view: what matters for valuation and deal work?

For business professionals evaluating canakinumab, the valuation drivers map tightly to:

• realized net pricing trends,
• payer access in top markets,
• patient retention and reauthorization pass rates,
• conversion of new diagnosed cases to treated patients.

A deal model should treat canakinumab revenue as:

• rare disease driven (diagnosis and specialist conversion),
• payer controlled (coverage, criteria, contracting),
• price sensitive (net pricing more important than list).

---

Market-dynamics and financial timeline (operational view)

Phase	Primary revenue engine	Market dynamic	Financial effect (typical)
Early/mid	Label fit and adoption	Pricing negotiation starts; patient onboarding ramps	Growth then flattening
Mature	Patient retention + incremental new starts	Payer tightening and tender outcomes	Stabilization with net price erosion
Later-maturity	Utilization management and competition	Formulary changes; indication-by-indication competitiveness	Slow decline or flat revenue unless price stabilizes

---

Key Takeaways

• Canakinumab’s market trajectory is driven by rare, severe IL‑1β mediated diseases, where demand is diagnosis and payer coverage dependent rather than broad population expansion.
• Financial performance has typically moved from adoption-led growth toward mature-phase stabilization, with net revenue pressured by contracting and utilization controls.
• The biggest financial swing factors are realized net pricing (rebates and tenders), patient retention and reauthorization, and payer preference versus IL‑1 alternatives.
• For commercial planning and valuation work, treat canakinumab revenue as rare-disease and payer-governed: quarterly outcomes usually reflect access and contracting more than treatment novelty.

---

FAQs

1) Why does canakinumab revenue depend heavily on payer coverage?

Because the eligible patient populations for CAPS and related IL‑1 driven diseases are narrow and require specialist diagnosis, payers can tightly control initiation and continued coverage through prior authorization and reauthorization criteria.

2) What is the most common pattern for mature canakinumab sales?

Stabilization supported by chronic-treatment retention, offset by net price erosion and utilization management. Sustained growth generally requires either expanded label access or improved net pricing.

3) How does competition in the IL‑1 pathway affect canakinumab?

Competition can shift formulary preference in overlapping indications, enable switching, and intensify tender pressure, all of which can reduce net pricing and utilization even when canakinumab’s clinical positioning remains strong.

4) Does tendering mainly impact sales volume or price?

It typically impacts net price first, but reduced payer coverage criteria can also affect volume by limiting patient starts and continuation.

5) What commercial metrics best predict near-term canakinumab revenue?

Net pricing (after rebates and contracting), treated patient persistence, reauthorization pass rates, and patient conversion rates from diagnosis to first dose.

---

References

[1] Novartis. Ilaris (canakinumab) prescribing information (US label). Novartis Pharmaceuticals Corporation.
[2] Novartis. Annual Report on Form 20‑F / Investor disclosures (product net sales by segment and major products; historical). Novartis.
[3] FDA. Ilaris (canakinumab) prescribing information. U.S. Food and Drug Administration.
[4] EMA. Ilaris (canakinumab) EPAR / product information. European Medicines Agency.